Literature DB >> 2525326

Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris.

B Silke1, S P Verma, M S Ali, E Goldhammer, S H Taylor.   

Abstract

The hemodynamic effects of nicorandil (20 mg) were compared with placebo in a double-blind study of 20 patients with angiographically proved coronary artery disease at rest before and 7, 15, 30 and 60 minutes after oral dosing. The impact of the drug on left ventricular (LV) hemodynamics and volume during exercise-induced angina was determined by repeating exercise 60 minutes after drug administration, at the same work load that reliably induced angina during control predrug exercise. At rest, nicorandil reduced all components of systemic arterial pressure without change in cardiac or stroke volume indexes or heart rate. Pulmonary artery occluded pressure was reduced without change in LV ejection fraction or systemic vascular resistance index. Effects were evident at 7 minutes and peaked at 30 minutes with attenuation at 60 minutes. Compared with control supine bicycle exercise, the drug (at 60 minutes) reduced mean systemic arterial pressure and LV filling pressure without change in cardiac stroke volume indexes and heart rate. There was a smaller increase in LV ejection fraction. These data suggested greatest impact on LV function during exercise when substantial decreases in filling pressure occurred at maintained cardiac pumping indexes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525326     DOI: 10.1016/0002-9149(89)90205-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Pharmacology and therapeutic effects of nicorandil.

Authors:  M Kinoshita; K Sakai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.

Authors:  A Markham; G L Plosker; K L Goa
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

3.  Nicorandil safety in the long-term treatment of coronary heart disease.

Authors:  S Witchitz; J Y Darmon
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

4.  Double-blind comparison of the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility.

Authors:  A Baumbach; U Braun; G Döring; K K Haase; W Voelker; K R Karsch
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

5.  A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.

Authors:  S Di Somma; V Liguori; M Petitto; A Carotenuto; D Bokor; O de Divitiis; M de Divitiis
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

6.  Pharmacokinetics of nicorandil in patients with normal and impaired renal function.

Authors:  M Molinaro; G Villa; M B Regazzi; A Salvadeo; S Segagni; R Rondanelli; E Sartirana
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 7.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

8.  Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers.

Authors:  M J Kool; J J Spek; H A Struyker Boudier; A P Hoeks; R S Reneman; R H van Herwaarden; L M Van Bortel
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.